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Treatment of infections is compromised worldwide by the emergence of bacteria that are 
resistant to multiple antibiotics. Although classically attributed to chromosomal muta-
tions, resistance is most commonly associated with extrachromosomal elements acquired 
from other bacteria in the environment. These include different types of mobile DNA 
segments, such as plasmids, transposons, and integrons. However, intrinsic mechanisms 
not commonly specified by mobile elements—such as efflux pumps that expel multiple 
kinds of antibiotics—are now recognized as major contributors to multidrug resistance in 
bacteria. Once established, multidrug-resistant organisms persist and spread worldwide, 
causing clinical failures in the treatment of infections and public health crises.Efforts aimed at identifying new antibiotics were once a 
top research and development priority among pharma-
ceutical companies. The potent broad spectrum drugs 
that emerged from these endeavors provided extraordi-
nary clinical efficacy. Success, however, has been com-
promised. We are now faced with a long list of microbes 
that have found ways to circumvent different structural 
classes of drugs and are no longer susceptible to most, 
if not all, therapeutic regimens.“There is probably no chemotherapeutic drug to which 
in suitable circumstances the bacteria cannot react 
by in some way acquiring ‘fastness’ [resistance].”
—Alexander Fleming, 1946The means that microbes use to evade antibiot-
ics certainly predate and outnumber the therapeutic 
interventions themselves. In a recent collection of soil-
dwelling Streptomyces (the producers of many clini-
cal therapeutic agents), every organism was multidrug 
resistant. Most were resistant to at least seven different 
antibiotics, and the phenotype of some included resist-
ance to 15–21 different drugs (D’Costa et al., 2006). 
Moreover, many isolates were resistant to daptomycin, 
quinupristin-dalfopristin, and telithromycin—all drugs 
approved by the United States Food and Drug Admin-
istration (FDA) within the last decade—as well as purely 
synthetic agents such as ciprofloxacin. These data not 
only suggest that our surroundings can act as a res-
ervoir for new (and old) resistance mechanisms, but that the drugs we use to treat infectious diseases have 
long-lasting effects outside of the hospital. Many anti-
microbial molecules exist for millennia stably within the 
environment (Cook et al., 1989), where they select and 
promote growth of resistant strains.
Resistance to single antibiotics became prominent in 
organisms that encountered the first commercially pro-
duced antibiotics. The most notable example is resist-
ance to penicillin among staphylococci, specified by an Celenzyme (penicillinase) that degraded the 
antibiotic (Barber, 1947). Over the years, 
continued selective pressure by different 
drugs has resulted in organisms bearing 
additional kinds of resistance mechanisms 
that led to multidrug resistance (MDR)—
novel penicillin-binding proteins (PBPs), 
enzymatic mechanisms of drug modifica-
tion, mutated drug targets, enhanced efflux pump expression, and altered membrane permeability. 
Some of the most problematic MDR organisms that are 
encountered currently include Pseudomonas aeruginosa 
(another microbe of soil origin), Acinetobacter bauman-
nii, Escherichia coli and Klebsiella pneumoniae bearing 
extended-spectrum β-lactamases (ESBL), vancomycin-
resistant enterococci (VRE), methicillin-resistant Staphy-
lococcus aureus (MRSA), vancomycin-resistant MRSA, 
and extensively drug-resistant (XDR) Mycobacterium 
tuberculosis (Table 1). Some like methicillin-resistant S. 
aureus couple MDR with exceptional virulence capabili-
ties (Miller et al., 2005). Others, including some strains of 
P. aeruginosa, A. baumannii, and K. pneumoniae, man-
age to evade every drug within the physician’s arsenal 
(Levin et al., 1999).l 128, March 23, 2007 ©2007 Elsevier Inc. 1037
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Bacteria can become antibiotic resistant (Abr) 
by mutation of the target gene in the chromo-
some. They can acquire foreign genetic material 
by incorporating free DNA segments into their 
chromosome (transformation). Genes are also 
transferred following infection by bacteriophage 
(transduction) and through plasmids and con-
jugative transposons during conjugation. The 
general term transposable element has been 
used to designate (1) an insertion sequence, (2) 
composite (compound), complex, and conjuga-
tive transposon, (3) transposing bacteriophage, 
or (4) integron.Rather than providing an extensive list of antibiotic 
resistance mechanisms (which can be found elsewhere 
[Alekshun and Levy, 2000]), the aim of this Review is to 
highlight common genetic and molecular mechanisms 
of resistance as they relate to important pathogens and 
to drugs used by physicians today.
Genetics of Multidrug Resistance
Bacterial antibiotic resistance can be attained through 
intrinsic or acquired mechanisms (Figure 1). Intrinsic 
mechanisms are those specified by naturally occurring 
genes found on the host’s chromosome, such as, AmpC 
β-lactamase of gram-negative bacteria and many MDR efflux systems (see below). Acquired 
mechanisms involve mutations in 
genes targeted by the antibiotic and 
the transfer of resistance determinants 
borne on plasmids, bacteriophages, 
transposons, and other mobile genetic material (Figure 1 and Table 2). In general, this exchange 
is accomplished through the processes of transduc-
tion (via bacteriophages), conjugation (via plasmids and 
conjugative transposons), and transformation (via incor-
poration into the chromosome of chromosomal DNA, 
plasmids, and other DNAs from dying organisms) (Levy 
and Marshall, 2004). Although gene transfer among 
organisms within the same genus is common, this proc-
ess has also been observed between very different 
genera, including transfer between such evolutionarily 
distant organisms as gram-positive and gram-negative 
bacteria (Courvalin, 1994). Plasmids contain genes for 
resistance and many other traits; they replicate inde-Table 1. General Characteristics of Multidrug-Resistant Organisms
Organism Common Infections Key Antibiotic Resistances
Drugs Considered for 
 Treatment of MDRa
P. aeruginosa Lung, wound β-lactams, fluoroquinolones, aminoglycosides Colistin
Acinetobacter spp. Lung, wound, 
bone, blood
β-lactams, fluoroquinolones, aminoglycosides Colistin, tigecycline
E. coli and K. 
 pneumoniae bear-
ing extended-spec-
trum β-lactamases
Urinary, biliary, 
gastrointestinal 
tracts, lung, blood
β-lactams, fluoroquinolones, aminoglycosides Colistin (for K. pneumoniae), 
tigecycline
Vancomycin-resist-
ant enterococci
Blood, heart,  
intra-abdominal
Vancomycin Quinupristin-dalfopristin, 
linezolid, daptomycin
Methicillin-resistant 
S. aureus
Skin and soft tis-
sue, respiratory 
tract, blood
β-lactams, fluoroquinolones, macrolides Quinupristin-dalfopristin, 
 daptomycin, linezolid,  
tigecycline, vancomycin
Multidrug-resistant 
S. pneumoniae
Ear, lung, blood, 
cerebrospinal fluid
β-lactams, macrolides, tetracyclines, co-trimoxazole Fluoroquinolones, tigecycline
Extensively 
drug-resistant M. 
 tuberculosis
Lung Rifampin, isoniazid, and three of the following: 
 aminoglycosides, polypeptides, fluoroquinolones, 
 thioamides, cycloserine, or para-aminosalicylic acid
3rd line agents, drug 
 combinations
aAgents either have been approved for use by a regulatory agency (e.g., FDA), have shown usefulness in treating infection, or 
exhibit promising in vitro activity and await a determination of clinical efficacy.
Table 2. Mobile Genetic Elements
Genetic Element General Characteristics Resistance Determinant(s) Specified/Examplesa
Plasmid Variable size (1- >100 kb), conjugative, and 
mobilizable
R factor: multiple resistances
Insertion sequence Small (<2.5 kb), contains terminal inverted 
repeats, and specifies a transposase
IS1, IS3, IS4, etc.
Composite (compound) 
transposon
Flanked by insertion sequences and/or 
inverted repeats
Tn5: Kan, Bleo, and Str
Complex transposon Large (>5 kb), flanked by short terminal 
inverted repeats, and specifies a  
transposase and recombinase
Tn1 and Tn3: β-lactamase 
Tn7: Tmp, Str, Spc 
Tn1546: glycopeptides
Conjugative transposon Promotes self-transfer Tn916: Tet and Mino 
Tn1545: Tet, Mino, Ery, and Kan
Transposable bacteriophage A bacterial virus that can insert into the 
 chromosome
Mu
Other transposable elements Other than composite, complex, and 
 conjugative transposons
Tn4: Amp, Str, Sul, and Hg 
Tn1691: Gen, Str, Sul, Cm, and Hg
Integron Facilitates acquisition and dissemination 
of gene cassettes; specifies an integrase, 
 attachments sites, and transcriptional 
 elements to drive expression of multiple 
resistance genes
Class 1: Multiple single determinants and MDR 
efflux pump (Qac)b 
Class 2: Tmp, Strp, Str, and Spc (Tn7) 
Class 3: carbapenems 
Class 4: Vibrio spp. super-integron
See Figure 1.
aAbbreviations: Amp, ampicillin; Bleo, bleomycin; Cm, chloramphenicol; Ery, erythromycin; Fus, fusidic acid; Gen, gentamicin; 
Hg, mercury; Kan, kanamycin; Mino, minocycline; Spc, spectinomycin; Str, streptomycin; Strp, streptothricin; Sul, sulfonamide; 
Tet, tetracycline; Tmp, trimethoprim; Van, vancomycin.
bSee Figure 2.pendently of the host chromosome and can be distin-
guished by their origins of replication. Multiple plasmids 
can exist within a single bacterium, where their genes 
add to the total genetics of the organism. Transposons 
are mobile genetic elements that can exist on plasmids 
or integrate into other transposons or the host’s chro-
mosome. In general, these pieces of DNA contain termi-
nal regions that participate in recombination and specify 
a protein(s) (e.g., transposase or recombinase) that 
facilitates incorporation into and from specific genomic 
regions. Conjugative transposons are unique in having 
qualities of plasmids and can facilitate the transfer of 
endogenous plasmids from one organism to another. 
Integrons contain collections of genes (gene cassettes) 
that are generally classified according to the sequence 
of the protein (integrase) that imparts the recombination 
function (Mazel, 2006) (Figure 2A). They have the abil-
ity to integrate stably into regions of other DNAs where 
they deliver, in a single exchange, multiple new genes, 
particularly for drug resistance. The super-integron, one 
which contains hundreds of gene cassettes (represent-
ing about ?3% of the host’s genome), is distinct from 
other integrons; it was first identified in Vibrio cholerae 
(Mazel et al., 1998).
Although Alexander Fleming selected and described 
mutants resistant to penicillin soon after he had dis-
covered the antibiotic, no one could have predicted the 
speed with which bacteria would acquire the capacity for dealing with multiple antibacterial agents. Plasmids, 
specifying a collection of individual antibiotic resistance 
determinants (originally termed resistance factors, R 
factors), were initially described as the vehicle used to 
rapidly spread resistance traits among bacteria. Strains 
of Shigella bearing the self-replicating and self-transfer-
able plasmids were easily selected and propagated dur-
ing a period of considerable sulfonamide use in Japan 
after World War II (Watanabe, 1963). Antibiotics such 
as streptomycin, chloramphenicol, and tetracycline 
were subsequently introduced for the treatment of the 
sulphonamide-resistant organisms. Shigella and E. coli 
strains bearing resistance to all four agents, however, 
were recognized in 1955 (Watanabe, 1963). Now, more 
than 60 years after antibiotics were first introduced into 
clinical practice, the prescience of Fleming has come to 
fruition as the infectious disease community has yet to 
identify an antibiotic that has managed to circumvent the 
development of resistance.
Resistance through Chromosomal Mutation
Fluoroquinolones
Virtually all clinically important fluoroquinolone resistance 
can be attributed to mutations within the drug’s targets, 
DNA gyrase and topoisomerase IV (Drlica and Malik, 
2003). These multisubunit complexes perform critical 
ATP-dependent functions during DNA replication; each 
is comprised of two subunits: GyrA and GyrB for DNA Cell 128, March 23, 2007 ©2007 Elsevier Inc. 1039
Figure 2. Transposable Elements that Confer Antibiotic Resistance
(A) Organization of a class 1 integron. int1 specifies the integrase (the recombination protein), att1 is the primary recombination site, attC are the 
59 base pair elements that are substrates of the integrase, and Pc is a common promoter that drives high-level expression of antibiotic resistance 
determinants (Abr) such as those for aminoglycosides, β-lactams, chloramphenicol, and trimethoprim inserted downstream of this element. qacE∆ 
and sul1 specify genes for resistance to quaternary ammonium compounds (partially deleted) and sulfonamides, respectively; these two genes are 
found specifically in class 1 integrons.
(B) The vanA gene cluster (adapted from Courvalin, 2006). Orf1 and Orf2 impart the transposition features. VanR (response regulator) and VanS 
(histidine kinase) comprise a two-component system that regulates expression of vanHAXYZ. VanA (ligase) and VanH (dehydrogenase) are respon-
sible for the synthesis of the modified depsipeptide (D-Ala-D-Lac, see text) while VanX (D,D-dipeptidase) and VanY (D,D-carboxypeptidase) cleave 
normal peptidoglycan substrates. VanZ is of unknown function. PR and PH are promoters that control expression of two separate transcriptional 
units, and the entire element is flanked by imperfect inverted repeats.gyrase and ParC/GrlA and ParE/GrlB for topoisomerase 
IV. The GyrA and ParC/GrlA proteins contain the DNA-
binding functions and are targeted by the fluoroquinolo-
nes (which are purely synthetic antibiotics), whereas 
GyrB and ParE/GrlB perform the roles of ATP binding and 
hydrolysis and are inhibited by coumarin antibiotics. In 
gram-negative bacteria, mutations in DNA gyrase occur 
first, whereas in gram-positive organisms mutations in 
topoisomerase IV arise initially in the stepwise movement 
to clinically relevant fluoroquinolone resistance.
Mutations that give rise to fluoroquinolone resistance 
are predominantly found in the quinolone-resistance-
determining-region (QRDR) of GyrA and ParC/GrlA. 
Mutations occur more frequently at particular amino 
acids than at others. Multiple mutational events can be 
selected in a stepwise manner so as to “train” resist-
ance in a bacterium; successive mutations have additive 
effects. Isolates that are highly fluoroquinolone resist-
ant bear multiple QRDR mutations and generally other 
mechanisms of fluoroquinolone resistance, such as 
drug efflux (see below).
Rifamycins
Rifamycins are bactericidal drugs that arrest transcrip-
tion by interacting with RpoB, the β subunit of RNA 
polymerase (RNAP). Although combination regimens 1040 Cell 128, March 23, 2007 ©2007 Elsevier Inc.that include rifampin or rifapentine and isoniazid, pyrazi-
namide, ethambutol, or streptomycin remain primary 
choices for front-line therapy of M. tuberculosis infection, 
resistance through point mutations in the rifampin-bind-
ing region of rpoB occur at a frequency of 1 × 10−8 and 
are widespread. M. tuberculosis resistant to rifampin and 
isoniazid at a minimum are defined as multidrug resist-
ant and impede successful therapy among patients in all 
regions of the world (Sharma and Mohan, 2006).
Sulfonamide and Trimethoprim Antibiotics
The sulfonamides, the first antimicrobials developed for 
large-scale introduction into clinical practice (in 1935), 
target dihydropteroate synthase. Their serendipitous 
discovery (the antibacterial activity was seen initially in 
vivo when the active compound was released as part of 
a dye) pales only in comparison with that of Fleming’s 
chance discovery of penicillin (Levy, 2002). Trimetho-
prim, introduced in 1968, inhibits dihydrofolate reductase 
and was the last structurally unique antibiotic approved 
prior to the release of linezolid in 2000. Mutations in the 
gene specifying dihydropteroate synthase decrease the 
enzyme’s affinity for the sulfonamides and have been 
found in laboratory experiments using E. coli and Strep-
tococcus pneumoniae and in clinical isolates of Campy-
lobacter jejuni and Haemophilus influenzae (Skold, 
2001). Mutations in the chromosomal gene specifying 
dihydrofolate reductase can result in overexpression of 
an enzyme with a reduced affinity for trimethoprim and 
thereby offer very high-level trimethoprim resistance in 
E. coli and H. influenzae (Skold, 2001).
Tetracycline, Aminoglycoside, and MLS Antibiotics
Agents within the tetracycline, aminoglycoside and mac-
rolide-lincosamide-streptogramin (MLS) classes of anti-
biotics target the ribosome to inhibit protein translation. 
As a consequence, resistance via chromosomal muta-
tion is uncommon. Tetracyclines and aminoglycosides 
interact with 16S rRNA (rrs) and the macrolide-lincosa-
mide-streptogramin (MLS) family binds to 23S rRNA 
(rrl). In most bacteria, multiple rrs and rrl operons are 
present and susceptibility mediated by any one of these 
targets can be dominant, making resistance difficult to 
attain without a mutation in all or a majority of the other 
operons. However, in organisms with low rRNA (rrn) copy 
numbers, chromosomal mutations conferring resistance 
have appeared. Tetracycline resistance via a point muta-
tion in Propionibacterium acnes (3 rRNA operons) and 
Helicobacter pylori (2 copies of rrn) (Gerrits et al., 2002; 
Ross et al., 1998) has been documented. Mutations in 
rrs conferring resistance to amikacin and kanamycin 
and alterations in small ribosome protein S12 (rpsL) or 
rrs affecting streptomycin (all aminoglycoside drugs) 
susceptibility in clinical M. tuberculosis (1 rrn operon) 
have been described (Alangaden et al., 1998). The emer-
gence of resistance to erythromycin (a macrolide) dur-
ing therapy caused by mutant rrl in S. pneumoniae (4 
copies of rrn) has been reported (Musher et al., 2002). 
Moreover, mutations in the large ribosome protein L4 
(rplD) have also been shown to alter MLS susceptibil-
ity (Tait-Kamradt et al., 2000). The ketolides, recently 
introduced into clinical practice, were designed to cir-
cumvent macrolide resistance; nonetheless decreased 
susceptibility and resistance to telithromycin (a ketolide) 
have been found in S. pneumoniae with mutations in rrl, 
rplD, and large ribosome protein L22 (rplV ) (Hisanaga 
et al., 2005). Mutations in L22 also affect quinupris-
tin-dalfopristin (streptogramins that act individually in 
a bacteriostatic manner) susceptibility by affecting the 
synergistic relationship important to the combination’s 
bactericidal mechanism of action (references in Hersh-
berger et al., 2004).
Oxazolidinones
Linezolid (another protein synthesis inhibitor) was 
approved recently as an agent to treat methicillin-resist-
ant S. aureus and vancomycin-resistant enterococci 
infections. Its availability in both intravenous and oral 
formulations makes it useful for treating infections in 
both the hospital and community. Resistance to linezolid 
in laboratory studies has been linked to point mutations 
in rrl in S. aureus and E. faecalis. Now, clinical isolates of 
Staphylococcus epidermidis, S. aureus, Streptococcus 
oralis, Enterococcus faecium, and E. faecalis resistant to 
linezolid have been documented and many of the strains 
bear rrl mutations (Meka and Gold, 2004). As with the fluoroquinolones, the level of resistance in S. aureus 
increases with mutations in multiple rrl alleles (Wilson et 
al., 2003) leading to clinically relevant resistance.
Lipopeptides
Daptomycin (a drug acting on bacterial membranes) was 
approved by the FDA in 2003 and while it has been suc-
cessfully used for treating infections caused by methicil-
lin-resistant S. aureus and other gram-positive bacteria, 
treatment failures have been noted (Hayden et al., 2005). 
Laboratory experiments have established that mutations 
in multiple chromosomal loci (i.e., mprF, yycG, rpoB, 
and rpoC) affect daptomycin susceptibility (Friedman et 
al., 2006). With regard to mprF, which specifies a lysyl-
phosphatidylglycerol synthetase, similar mutations have 
been identified in nonsusceptible clinical isolates as well 
(Friedman et al., 2006).
Genomic Duplications
A mechanism for drug resistance common in eukaryotic 
cells (e.g., certain mammalian cancers and parasites) 
is gene amplification, which leads to overexpression 
of multidrug transporters and drug targets (Albertson, 
2006). Recently, a large tandem duplication of the E. 
coli acrAB locus in a mutant isolated in the presence of 
tetracycline was found to overexpress the AcrAB drug 
efflux pump, producing an MDR phenotype (Nicoloff 
et al., 2006). The mutants, however, were unstable and 
reverted to the wild-type phenotype in the absence of 
drug (Nicoloff et al., 2007). Genomic amplification has 
also been shown to affect susceptibility to methicillin in 
S. aureus (Matthews and Stewart, 1988). It is expected 
that examples of gene duplication as a mechanism of 
resistance, not mutation, will increase in recognition 
among bacterial isolates. The likely phenotype will be an 
unstable form of resistance.
Acquired Resistance: Enzymatic Drug Modification
Enzymes that modify antibacterial drugs are divided into 
two general classes: those such as β-lactamases that 
degrade antibiotics and others (including the macrolide 
and aminoglycoside-modifying proteins) that perform 
chemical transformations.
β-Lactam Antibiotics
There are hundreds of β-lactamases that have been dis-
covered and characterized, and a more complete over-
view of the individual enzymes within this protein family 
is available elsewhere (Jacoby and Munoz-Price, 2005). 
Most of these resistances are specified by genes located 
on plasmids and transposons; others are chromosomal 
and provide intrinsic resistance.
β-lactamases are classified using schemes based 
on function (the system of Bush-Jacoby-Medeiros) 
or structure (Ambler classification) but in general are 
broadly separated into enzymes with a serine active site 
and those that require a metal ion cofactor (references 
in Jacoby and Munoz-Price, 2005). The classification 
scheme of Ambler divides the β-lactamases into four 
groups: class A, C, and D enzymes are proteins with a Cell 128, March 23, 2007 ©2007 Elsevier Inc. 1041
serine residue at their active sites and the class B pro-
teins are zinc-dependent metalloenzymes. Some class 
A proteins function as extended-spectrum β-lactamases 
and as carbapenemases. The class B metallo-enzymes 
that hydrolyze carbapenems are susceptible to inhibi-
tion by EDTA, whereas they are not susceptible to inhi-
bition by clavulanate (a β-lactamase inhibitor). AmpC, 
an inducible and usually chromosomal enzyme found in 
many species of the Enterobacteriaceae and P. aerugi-
nosa, is the prototype class C enzyme. Recent reports 
have described plasmid-borne ampC genes that can 
be transferred among E. coli, Klebsiella spp., and Sal-
monella spp. (references in (Jacoby and Munoz-Price, 
2005). Class D enzymes have been found in only a few 
species such as P. aeruginosa, Acinetobacter spp., and 
Aeromonas spp.
Aminoglycosides
A large number of aminoglycoside-modifying enzymes 
specified by genes on transferable elements are wide-
spread in clinically relevant organisms (Davies and 
Wright, 1997). Here, resistance is accomplished with 
proteins that N-acetylate (acetyltransferases), phos-
phorylate (phosphotransferases), and adenylate (nucle-
otidyltransferases) the aminoglycosides. The acetyl-
transferases are capable of modifying tobramycin, 
gentamicin, netilmicin, and amikacin; the nucleotidyl-
transferase proteins alter the activity of tobramycin; and 
the phosphotransferases affect amikacin susceptibility. 
Many of the aminoglycoside-modifying enzymes are 
found on integrons and other mobile genetic elements 
where they associate with additional resistance determi-
nants. For example, three acetyltransferase genes were 
found on a class 1 integron from P. aeruginosa that also 
specified resistance to carbapenems and sulfonamides 
(Poirel et al., 2001).
MLS Antibiotics
There are a number of inactivating enzymes that act on 
the MLS antibiotics. The genes encode esterases, hydro-
lases, glycosylases, phosphotransferases, nucleotidyl-
transferases, and acetyltransferases and are found less 
frequently than efflux and ribosome-modifying genes in 
clinical isolates (Weisblum, 1998). Esterases act on 14- 
(e.g., erythromycin) and 15- (e.g., azithromycin) mem-
bered macrolides; the hydrolases affect streptogramin 
B drugs; the acetyltransferases inactivate streptogramin 
A antibiotics; and the nucleotidyltransferases confer 
resistance to the lincosamides (e.g., clindamycin). Phos-
photransferases modify 14-, 15-, and 16-membered 
macrolides with varying specificities and telithromycin 
(Matsuoka and Sasaki, 2004).
Chloramphenicol
Acetyltransferases that inactivate chloramphenicol (a 
generally bacteriostatic inhibitor of protein synthesis) 
are the most common resistance mechanisms for this 
antibiotic and are separated into type A and B proteins 
(Schwarz et al., 2004). Both types of enzymes func-
tion as homotrimers but are unrelated based on amino 
acid sequence analyses. The type B enzymes are also 1042 Cell 128, March 23, 2007 ©2007 Elsevier Inc.termed xenobiotic acetyltransferases and appear to 
share an evolutionary lineage that includes some strep-
togramin-inactivating enzymes found in the enterococci 
and staphylococci. Constitutive expression as well as 
translational attenuation underlie the regulation of type 
A and B proteins.
Tetracyclines
Recently, a flavin-dependent monooxygenase, desig-
nated tet(X), originally identified in Bacteroides fragilis, 
that acts on older tetracyclines (such as tetracycline, 
oxytetracycline, and chlortetracycline) as well as newer 
compounds (such as doxycycline, minocycline, and 
tigecycline) has been characterized (Moore et al., 2005). 
The enzyme catalyzes regioselective hydroxylation to 
inactivate its substrates, but the modification products 
produced by TetX are not stable at physiological pH. 
The tet(X) determinant has not yet been found in com-
mon, clinically relevant tetracycline-resistant isolates, 
although a related tet(X)-like gene in P. aeruginosa has 
been reported (A. Nakamura et al., 2002, paper pre-
sented at Interscience Conference on Antimicrobial 
Agents and Chemotherapy, San Diego, CA).
Altered, Substituted, and Protected Drug Targets
β-Lactam Antibiotics
The first penicillin-resistant S. aureus identified in the 
mid-1940s expressed a β-lactamase (termed PCI) that 
afforded resistance. A penicillin derivative, methicillin, 
that was resistant to this β-lactamase was subsequently 
introduced in 1959 to treat the penicillin-resistant iso-
lates, but methicillin-resistant S. aureus were identified 
shortly thereafter (Barber, 1961). Here, the β-lactam 
resistance was linked to the acquisition of a gene for 
an altered PBP. Resistance in the staphylococci (Fuda 
et al., 2005) and streptococci (Jacobs, 1999) frequently 
occurs following the acquisition of genes for PBPs that 
are not sensitive to β-lactam inhibition. The altered PBP 
of methicillin-resistant S. aureus, PBP2a, is specified 
by mecA and is transported on a mobile genetic ele-
ment called the “staphylococcal cassette chromosome” 
(SCCmec) (Fuda et al., 2005). In addition to mecA, 
SCCmec contains the mecR1-mecI regulatory loci and 
encodes the enzymes that are involved in site-specific 
recombination.
Under normal circumstances, S. aureus uses multi-
ple PBPs during cell wall biosynthesis. One, PBP2, is a 
bifunctional enzyme with transpeptidase and transgly-
cosylase activities. When methicillin-resistant S. aureus 
is exposed to methicillin, PBP2 functions as the transg-
lycosylase whereas PBP2a contributes the transpepti-
dase activity in order to confer resistance to nearly all 
β-lactam antibiotics. Removal of the transglycosylase 
function of PBP2 imparts β-lactam susceptibility and 
demonstrates the importance of both attributes of the 
enzyme (reviewed in Fuda et al., 2005).
The new strains of methicillin-resistant S. aureus that 
have emerged recently outside of hospitals in the com-
munity share some features with hospital-associated 
strains (Naimi et al., 2003). These include the nearly 
complete β-lactam resistance phenotype and the abil-
ity to cause a range of serious life-threatening infec-
tions. Although many community-associated strains are 
multidrug susceptible (except to β-lactam antibiotics), 
the genome of an epidemic clone distributed through-
out the US (USA300) contains chromosomal mutations 
that confer fluoroquinolone resistance and plasmids that 
mediate resistance to tetracycline, erythromycin, clin-
damycin, streptogramin B agents, and mupirocin (Diep 
et al., 2006).
Glycopeptides
Glycopeptides (including vancomycin and teicoplanin) 
interact with peptidoglycan precursors to exert bacteri-
cidal activity. Resistance to the glycopeptides in gram-
positive cocci is another illustration of an altered drug 
target (Courvalin, 2006). In the enterococci, acquired 
glycopeptide resistance is attributable to VanA, B, D, 
E, and G phenotypes whereas VanC affords intrinsic 
resistance. VanA and VanD provide resistance to both 
vancomycin and teicoplanin, whereas the others provide 
resistance to vancomycin alone. The resistance phe-
notype is accomplished using multiple proteins speci-
fied in gene clusters and each result in the production 
of a modified peptidoglycan. Of the many drug-resist-
ance determinants currently known, the determinant for 
glycopeptide resistance is probably the most complex 
(Figure 2B).
The activity of many enzymes specified by the gene 
cluster are involved in conferring glycopeptide resist-
ance (Figure 2B). Either a racemase or dehydrogenase 
results in the production of serine (VanC, E, or G) or lac-
tate from pyruvate (VanA, B, or D), which a ligase uses 
to form a C-terminal D-Ala-D-Ser or D-Ala-D-Lac in the 
altered peptidoglycan. A two-component regulatory 
system controls expression of the biosynthetic machin-
ery. Although the glycopeptides have a lower affinity 
for the D-Ala-D-Ser or D-Ala-D-Lac substrates, they 
can still bind and inhibit peptidoglycan biosynthesis if 
an intact D-Ala target remains. Two additional enzymes 
(or a single bi-functional protein for VanC) complete the 
phenotype by removing the antibiotic’s normal target: 
a dipeptidase cleaves the C-terminal D-Ala-D-Ala and 
a carboxypeptidase provides a redundant function of 
removing the terminal D-Ala in the absence of, or under 
circumstances when, the dipeptidase is less active.
Recently, the enterococcal vanA gene cluster has 
made its way into methicillin-resistant S. aureus, impart-
ing full-blown vancomycin resistance on this prominent 
pathogen (Weigel et al., 2003), although this molecular 
event had been demonstrated in laboratory experiments 
years before (Noble et al., 1992). Vancomycin-resistant 
S. aureus have now been identified in patients from three 
different US locales, Michigan, Pennsylvania, and New 
York. In all instances, the resistance determinant resides 
on a plasmid-specified transposon, Tn1546. Vanco-
mycin-resistant E. faecalis and methicillin-resistant S. 
aureus were also obtained from the Michigan patient that bore vancomycin-resistant S. aureus and each con-
tained plasmids that were identical, except for the pres-
ence of Tn1546 in the isolate of vancomycin-resistant E. 
faecalis. It is assumed that the plasmid from E. faecalis 
was the vehicle for vanA entry into S. aureus and that 
the vanA gene cluster was subsequently transferred by 
means of transposition into the S. aureus plasmid.
Tetracyclines and MLS Antibiotics
The most prevalent forms of resistance to the tetracy-
clines in the clinic are drug efflux (see below) and ribos-
ome protection. Determinants of ribosome protection 
(Connell et al., 2003) have sequence similarity to bacte-
rial elongation factors (EF-G an EF-Tu). They also pos-
sess GTPase activity and function to facilitate release 
of tetracycline from the ribosome in an energy-depend-
ent manner (Connell et al., 2003). Bacteria that exhibit 
resistance to minocycline generally contain a ribosome 
protection determinant.
In Megasphaera elsdenii (a rumen bacterium), a 
mosaic gene containing two unique ribosome protec-
tion determinants (TetO and TetW) has been described 
(Stanton and Humphrey, 2003). Moreover, the tet(P) 
determinant of Clostridium perfringens specifies both 
ribosome protection and efflux mechanisms in an over-
lapping genetic unit (Sloan et al., 1994).
Binding of drugs within the MLSK (macrolide-lin-
cosamide-streptogramin-ketolide) family to 23S rRNA 
is affected by erm (erythromycin resistance methylase 
or erythromycin ribosome methylation) specified gene 
products (Zhanel et al., 2001). These mechanisms repre-
sent the predominant macrolide resistance mechanisms 
in Europe and South Africa. Currently, there are 34 dif-
ferent classes of Erm proteins (http://faculty.washington.
edu/marilynr/), and each functions by methylating a 
single adenine residue of the E. coli 23S rRNA (at posi-
tion A2058). Methylation results in the MLSB phenotype, 
which encompasses resistance to 14-, 15-, and 16-mem-
bered macrolides, lincosamides, and streptogramin B 
drugs. Some of the resistance determinants are induced 
following exposure to MLS drugs, whereas others are 
constitutively synthesized. In the staphylococci, agents 
like erythromycin and azithromycin induce erm expres-
sion, but 16-membered macrolides do not (Zhanel et 
al., 2001). Constitutive erm expression in some clinical 
and laboratory strains confers telithromycin resistance 
(Hisanaga et al., 2005).
Sulfonamide and Trimethoprim Antibiotics
The activities of the sulfonamides and trimethoprim are 
also affected by acquired genes specifying enzymes 
that are insensitive to drug inhibition (Skold, 2001). sul1 
and sul2 are the main determinants of clinical resistance 
to sulfonamide, whereas sul3 was found to be prevalent 
in farm animals (Perreten and Boerlin, 2003). In contrast, 
more than 20 trimethoprim resistance determinants 
(numbered chronologically from dfr1) are documented. 
The genes specifying the sulfonamide-insensitive dihy-
dropteroate synthases are present on class 1 integrons 
(sul1) or plasmids (sul2), whereas dfr variants (with dfr1 Cell 128, March 23, 2007 ©2007 Elsevier Inc. 1043
Figure 3. Antibiotic Efflux Systems
For simplicity, the illustration represents a 
gram-negative bacterium. Some substrates 
of AcrAB (e.g., aminoglycosides) are presum-
ably recognized by a portion of AcrB that 
faces the cytoplasm while others (e.g., tetra-
cycline) migrate thorough the inner membrane 
to an AcrB-binding pocket(s) (Murakami and 
Yamaguchi, 2003). The E. coli AcrAB-TolC 
and Tet efflux systems are secondary trans-
porters that use proton motive force (H+) while 
NorM (Vibrio spp.) is a secondary transporter 
that exploits a gradient of sodium ions (Na+) 
to drive efflux (Li and Nikaido, 2004). MacAB 
is a primary transporter that uses the energy 
derived from ATP hydrolysis to drive efflux (Li 
and Nikaido, 2004). Single-component sys-
tems (e.g., NorM, Tet) transport substrates 
across the inner membrane where they then 
diffuse through porins (e.g., OmpF) or the 
outer membrane into the extracellular medium (Li and Nikaido, 2004). Multicomponent systems like AcrAB-TolC and MacAB-TolC direct the 
transport of substrates to the extracellular medium. Abbreviations: LPS, lipopolysaccharide; Ab, antibiotic; Tc, tetracycline; Mac, macrolide.being the most common in gram-negative bacteria) 
move from organism to organism on class 1 and 2 inte-
grons. dfr1 is present on the Tn7 transposon, thereby 
facilitating its integration into the E. coli chromosome.
Fluoroquinolones
The plasmid-specified qnr determinants provide an 
unusual mechanism of decreased fluoroquinolone sus-
ceptibility. Variants of the qnr element, first identified in 
K. pneumoniae (Martinez-Martinez et al., 1998), have 
been found in E. coli, Enterobacter cloacae, Providencia 
stuartii, Citrobacter freundii, C. koseri, Shigella flexneri 
2b, and non-Typhi Salmonella enterica. Qnr belongs to 
the pentapeptide repeat family of proteins and medi-
ates resistance presumably by protecting DNA gyrase 
and topoisomerase IV from the inhibitory action of the 
fluoroquinolones (Tran and Jacoby, 2002). Another fluo-
roquinolone resistance mechanism, MfpA, has been 
found in M. tuberculosis, which contains a single type II 
topoisomerase (Hegde et al., 2005). It, too, is a member 
of the pentapeptide repeat family of proteins but also 
acts as an inhibitor of DNA gyrase from M. tuberculosis 
by virtue of its ability to mimic the structure of B-form 
DNA. The interaction of MfpA with DNA gyrase likely 
interferes with the inhibitory action of agents like cipro-
floxacin. By themselves, Qnr and MfpA confer only low 
levels of fluoroquinolone resistance but can augment 
resistance when coupled with other mechanisms (see 
below). Moreover, selection for fluoroquinolone resist-
ance may be favored in organisms bearing Qnr or MfpA 
if they survive the presence of low fluoroquinolone con-
centrations.
Efflux Systems, Porins, and Altered Membranes
Efflux as a mechanism of antibiotic resistance was 
originally described for tetracyclines (McMurry et al., 
1980) and is now well-appreciated and commonly 
found. Most drug efflux proteins belong to five dis-
tinct protein families: the resistance-nodulation-cell 
division (RND), major facilitator (MF), staphylococcal/
small multidrug resistance (SMR), ATP-binding cas-1044 Cell 128, March 23, 2007 ©2007 Elsevier Inc.sette (ABC), and multidrug and toxic compound extru-
sion (MATE) families (Li and Nikaido, 2004). Efflux by 
proteins in the RND, SMR, MF, and MATE families is 
driven by proton (and sodium) motive force and is 
therefore called secondary transport (Figure 3). ATP 
hydrolysis drives efflux in the primary (ABC) transport-
ers (Figure 3). Efflux proteins also come in two general 
types. Some, like the tetracycline (Tet) (Levy, 1992) 
and macrolide (Mef) (Zhanel et al., 2001) transporters, 
are single component efflux systems that have narrow 
substrate profiles, acting on a few agents or multiple 
agents within the same drug class. Others, such as 
the RND family members, require two additional pro-
teins to confer resistance but are capable of binding 
multiple structurally unrelated compounds and confer 
broad resistance phenotypes (Li and Nikaido, 2004). 
The organizations of the RND-based efflux systems, 
which are found in a number of gram-negative bacte-
ria, allow them to transport drugs from the cytoplasm 
and across the inner and outer membranes of the cell 
envelope (Figure 3).
Tetracyclines
There are now more than 20 different tetracycline efflux 
proteins that have been allocated to six different groups 
(Sapunaric et al., 2005). The proteins contain either 12- 
(e.g., TetA-E in gram-negative bacteria) or 14- (e.g., TetK 
and TetL in gram-positive organisms) putative trans-
membrane-spanning segments. Expression of proteins 
within group 1 is controlled by a transcription repressor 
such as TetR. The antibiotic inactivates the repressor 
and allows expression of the tetracycline efflux systems. 
Alternatively, synthesis of TetK and TetL is inducible by 
tetracyclines through mechanisms that involve trans-
lation attenuation and reinitiation, respectively. Also, 
the mechanism of tetracycline efflux is not conserved 
among all members; some, such as Tet(B), engage in 
electroneutral reactions (that is, one tetracycline-Mg 
chelate exits the cell as a proton enters whereas others, 
such as TetL, accomplish efflux in an electrogenic man-
ner [references in Sapunaric et al., 2005]).
MLS Antibiotics
MsrA (macrolide-streptogramin resistance) is an ABC 
efflux protein that produces resistance to 14- and 15-
membered macrolides and streptogramin B antibiotics in 
the streptococci and staphylococci, but susceptibility to 
clindamycin is not affected by this system (Li and Nikaido, 
2004). In the staphylococci, relatives of MsrA (VgaA and 
VgaB) are specified on plasmids. VgaA confers resist-
ance to streptogramin A antibiotics and lincosamides, 
and VgaB affects pristinamycin (a mixture of strepto-
gramin A and B antibiotics) susceptibility (Chesneau 
et al., 2005). Alternatively, the Mef efflux transporters, 
which are the predominant macrolide resistance proteins 
in the United States, effectively handle 14- and 15-mem-
bered macrolides in the streptococci, but strains that 
express the proteins are susceptible to 16-membered 
macrolides, lincosamides, and streptogramin B drugs 
(Li and Nikaido, 2004). E. faecalis are naturally resist-
ant to quinupristin-dalfopristin and this characteristic 
is attributed to the expression of lsa, which specifies a 
streptogramin efflux protein belonging to the ABC family, 
as mutational inactivation of Lsa confers susceptibility 
to quinupristin-dalfopristin in this organism (references 
in Hershberger et al., 2004). This scenario has been 
observed with other (MDR) efflux proteins where removal 
of an efflux system renders an organism susceptible to 
antibiotics, even in the presence of chromosomal muta-
tions that reduce binding of the drug to its target and 
would otherwise confer clinical resistance (Lomovskaya 
et al., 1999; Oethinger et al., 2000).
Phenicols
Chloramphenicol and florfenicol are broad-spec-
trum agents that have utility in human clinical practice 
(chloramphenicol) and animal husbandry (florfenicol). 
Because of toxicity (aplastic anemia) seen with the 
former, the current use of chloramphenicol has been 
limited to the treatment of some severe life-threatening 
infections such as bacterial meningitis in patients with 
allergies to the penicillins. Efflux proteins specific for the 
phenicols have been described in a number of clinically 
important bacteria and are classified into eight different 
groups (E-1 through E-8) (Schwarz et al., 2004). In gen-
eral, these proteins provide levels of resistance greater 
than that of the multidrug efflux proteins described below, 
and members of groups E-3 and E-4 confer resistance 
to both phenicols. For some chloramphenicol-specific 
efflux proteins like CmlA, expression of the resistance 
determinant is mediated through an inducible mecha-
nism of translational attenuation similar to that used for 
particular chloramphenicol acetyltransferase resistance 
genes (see above).
Multidrug Resistance Efflux Systems
Historically, the gram-negative cell envelope was thought 
to affect antibiotic susceptibility by greatly restricting 
drug penetration (Li and Nikaido, 2004). Contemporary 
studies, however, have shown that most antibacterial 
agents effectively penetrate gram-negative organisms 
(Li and Nikaido, 2004) but fail to reach intracellular tar-gets because of efflux (Levy, 1992). In gram-negative 
bacteria, including E. coli and nonfermenting organisms 
such as P. aeruginosa, Acinetobacter spp., Stenotropho-
monas maltophilia, and Burkholderia cepacia, “intrinsic” 
resistance is attributed to the expression of the RND 
efflux system(s) (Figure 3). This mechanism is an effec-
tive means for dealing with different antibiotic classes 
using a single resistance determinant. The natural func-
tion of the E. coli AcrAB efflux system is thought to have 
evolved to protect the cell from the inhibitory activity 
of toxic substances such as bile salts (Li and Nikaido, 
2004). Other related systems function similarly in Neis-
seria gonorrhoeae (Hagman et al., 1995) and export 
molecules involved in quorum sensing in P. aeruginosa 
(Pesci et al., 1999).
Tigecycline, which gained FDA approval in 2005, has 
poor activity against P. aeruginosa, Proteus mirabilis, 
Morganella morganii, and Klebsiella pneumonia; this is 
attributed to RND efflux systems (references in Stein 
and Craig, 2006). Elimination of an AcrA ortholog in M. 
morganii, MexXY-OprM in P. aeruginosa, and an AcrB 
ortholog in P. mirabilis increased susceptibility to tige-
cycline 16- to 133-fold (references in Stein and Craig, 
2006), whereas deletion in E. coli of AcrAB and AcrEF 
had a more modest (4-fold) effect (Hirata et al., 2004).
Bacillus subtilis Bmr (Bacillus multidrug resistance) 
(Neyfakh et al., 1991) and S. aureus Qac (quaternary 
ammonium compound) (Tennent et al., 1989) are two 
MDR efflux proteins (members of the MF superfamily) 
that were first characterized in gram-positive cells. Like 
many members of the RND family in gram-negative 
bacteria, Bmr is constitutively expressed and therefore 
engenders intrinsic resistance to chloramphenicol and 
fluoroquinolones. Another MDR efflux pump from B. 
subtilis, Blt, includes spermidine among its list of sub-
strates. It is now thought that the natural function of Blt 
is to facilitate the removal of polyamines from the cell 
(Woolridge et al., 1997). The staphylococcal Qac sys-
tems provide resistance to antiseptics and disinfectants 
(e.g., quaternary ammonium compounds, chlorhexidine, 
and diamidines). Unlike most other MDR efflux proteins, 
these are specified on plasmids, a feature that facilitates 
their dissemination.
Permeability
As alluded to previously, the outer membrane of the 
gram-negative cell envelope is a barrier to both hydro-
phobic and hydrophilic compounds. In order to circum-
vent this permeability barrier, these organisms have 
evolved porin proteins (e.g., OmpF in E. coli and OprD 
in P. aeruginosa) that function as “nonspecific” entry 
and exit points for antibiotics and other small-molecule 
organic chemicals. Imipenem (and to a lesser extent 
meropenem) and basic amino acids pass through OprD; 
mutations that decrease expression of the porin con-
tribute to clinical imipenem resistance. Moreover, the 
expression of OprD and the MexEF-OprM efflux system 
is coregulated (Ochs et al., 1999), and in this manner 
resistance to the carbapenems and other substrates of Cell 128, March 23, 2007 ©2007 Elsevier Inc. 1045
Table 3. MDR Efflux Systems of Clinically Important Bacteria
Bacterial Organism Efflux System(s) Representative Antibiotic Resistancea
P. aeruginosa MExAB-OprM BLA and FQ
MexCD-OprJ 4th gen ceph
MexEF-OprN FQ, Cm, Tmp, and Tri
MexHI-OprD EtBr, Nor, and Acr
MexJK-OprM Cip, Tet, Ery, and Tri
MexVW-OprM FQ, Cm, Tet, Ery, EtBr, and Acr
MexXY-OprM AG and Tig
A. baumannii AdeABC AG, FQ, TET, Ctx, Cm, Ery, and Tmp
S. maltophilia SmeABC AG, BLA, and FQ
SmeDEF MC, TET, FQ, CAR, Cm, and Ery
B. cepacia CeoAB-OpcM Cm, Cip, and Tmp
B. pseudomallei AmrAB-AprA MAC and AG
E. coli AcrAB-TolC FQ, BLA, TET, Cm, Acr, Tri
K. pneumoniae AcrAB-TolC FQ, BLA, TET, and Cm
S. aureus MepA Tig, Mino, Tet, Cip, Nor EtBr, and TPP
E. faecalis EmeA Nor, EtBr, Clind, Ery, and Nov
Lsa Clind and QD
S. pneumoniae PmrA FQ, Acr, and EtBr
aAbbreviations: 4th gen ceph, fourth-generation cephalosporins; Acr, acriflavin; AG, aminoglycosides; BLA, β-lactams; CAR, 
carbapenems; Cip, ciprofloxacin; Clind, clindamycin; Cm, chloramphenicol; Ctx, cefotaxime; Ery, erythromycin; EtBr, ethidium 
bromide; FQ, fluoroquinolones; MC, macrolides; Mino, minocycline; Nor, norfloxacin; Nov, novobiocin; QD, quinupristin-dalfo-
pristin; TET, tetracycline family; Tet, tetracycline; Tig, tigecycline; Tmp, trimethoprim; TPP, tetraphenylphosphonium bromide; 
Tri, triclosan.MexEF-OprM (Table 3) can develop in mutants where 
the expression of OprD and the efflux pump has been 
altered.
In 1996, Hiramatsu and colleagues identified clinical S. 
aureus isolates in Japan that exhibited an intermediate 
level of resistance to vancomycin (the vancomycin inter-
mediate-resistant S. aureus [VISA] strains) (Hiramatsu 
et al., 1997), and shortly thereafter additional organisms 
with a glycopeptide-insensitive phenotype appeared in 
the United States (the GISA isolates). A prominent feature 
of the VISA isolates is the presence of a thickened cell 
wall. It is presumed that this property traps vancomycin 
and prevents the antibiotic from reaching its target (Cui 
et al., 2006a). More recently, the same group performed 
a preliminary characterization of the VISA isolates and 
found reduced susceptibility to daptomycin (Cui et al., 
2006b). Although additional molecular and biochemical 
characterizations are certainly needed, the findings do 
carry a cautionary note.
Mutations that offer resistance to polymyxin B in P. 
aeruginosa presumably involve changes in the bacte-
rial cell envelope that do not involve porins (references 
in Falagas and Kasiakou, 2005). In Salmonella enterica 
serovar Typhimurium, PmrAB (a two-component regula-
tory system) regulates resistance to polymyxin by modi-1046 Cell 128, March 23, 2007 ©2007 Elsevier Inc.fying lipopolysaccharide and lipid A (references in Fala-
gas and Kasiakou, 2005). The RosAB efflux system of 
Yersinia enterocolitica also affects susceptibility to poly-
myxin B (references in Falagas and Kasiakou, 2005).
Regulatory Genes in Multidrug Resistance
Chromosomal loci specifying global regulatory proteins 
that control MDR have been characterized in bacteria 
including E. coli, K. pneumoniae, and other Enterobac-
teriaceae, Neisseria gonorrhoeae, Bacillus subtilis, and 
S. aureus (Grkovic et al., 2002). In most instances, the 
regulatory proteins act as activators or repressors of 
transcription and contain either a single DNA-binding 
domain or two separate regions responsible for DNA 
binding and interacting with small-molecule substrates 
(Schumacher and Brennan, 2002). In the case of E. coli 
MarA, the protein regulates the expression of a large 
number of other chromosome genes (the Mar regulon), 
including those specifying an MDR efflux pump and other 
proteins (e.g., porins) that mediate antibiotic susceptibil-
ity (Barbosa and Levy, 2000). In a clinical K. pneumoniae 
isolate exhibiting reduced susceptibility to tigecycline 
and an MDR phenotype, transposon mutagenesis was 
used to find that inactivation of ramA, which specifies a 
MarA ortholog, produced a 16-fold increase in suscep-
tibility to tigecycline and abrogated the MDR phenotype 
(Ruzin et al., 2005). Although other clinical isolates that 
overexpress MarA or a MarA ortholog and exhibit a MDR 
phenotype have been described previously (Schneiders 
et al., 2003 and references therein), the studies that 
involved K. pneumoniae offer further proof that chro-
mosomal transcription factors that regulate MDR efflux 
systems can produce clinical drug resistance.
Single Determinants of Multidrug Resistance
Except for the case of MDR efflux pumps, a single resist-
ance mechanism commonly affords protection against 
one antibiotic or, at the most, drugs within the same 
general class, e.g., PBP2 of MRSA. Still, resistance 
determinants that specify erythromycin (Erm) methyl-
transferases in a variety of pathogens are single pro-
teins that give rise to macrolide, lincosamide, and type 
B streptogramin resistance: structurally unique agents 
that share a common target and mechanism of action 
(Roberts, 2004).
A mutant aminoglycoside acetyltransferase (specified 
by aac(6’)-Ib-cr) that gave rise to aminoglycoside (ami-
kacin, kanamycin, and tobramycin) and fluoroquinolone 
(ciprofloxacin and norfloxacin) resistance was identified 
recently (Robicsek et al., 2006). Although the level of 
resistance conferred was low, aac(6’)-Ib-cr was located 
on a plasmid bearing another unusual mechanism (the 
qnr determinant [see above]) of fluoroquinolone resist-
ance, and the two determinants together functioned in 
an additive manner to yield clinical levels of fluoroqui-
nolone resistance.
Reduced susceptibility to the macrolides, chloram-
phenicol, and linezolid in clinical S. pneumoniae iso-
lates has been attributed to mutations in large ribosomal 
protein (L4) (Wolter et al., 2005). Although mutations in 
the genes that specify 23S rRNA, L4, or L22 commonly 
lead to macrolide resistance, susceptibility to chloram-
phenicol frequently occurs following the acquisition of 
a modifying enzyme (see above). For linezolid, previous 
resistance in the enterococci and S. aureus was attrib-
uted solely to mutations in the locus that encodes 23S 
rRNA (see above).
What the Past Can Teach Us about the Future
More than half a century has passed since the first anti-
biotics were introduced commercially. It did not take 
long for microbes to develop “drug fastness” to the 
original “magic bullets,” and widespread use of many 
antibacterial drugs provides ideal conditions for the 
spread of MDR organisms. Many early researchers were 
expertly skilled in identifying the means used to evade 
the inhibitory effects of these drugs—from investigators 
such as Esther and Joshua Lederberg, who character-
ized the random nature of mutational events conferring 
resistance to streptomycin, to others such as Tsutomu 
Watanabe, who surmised that mutation alone would not 
be sufficient for explaining the MDR phenotype. Resist-
ance transfer factors (RTFs), later called resistance (R) factors and then plasmids, would provide the basis for 
multiple drug resistance caused by “infective heredity” 
(reviewed in Watanabe, 1963).
For bacteria, there is more than one way to evade a 
drug class, and organisms unresponsive to all antimi-
crobial agents, even ones not encountered previously, 
are now familiar. Microbes have means for collecting 
single resistance traits. Theoretically, one needs only a 
single (broad-spectrum) agent that effectively deals with 
resistances affecting just one class of drugs. The MDR 
efflux pumps that render multiple classes ineffective, 
however, have greatly confounded efforts in finding new 
agents.
Multidrug resistance is a worldwide problem that does 
not obey international borders and can indiscriminately 
affect members of all socioeconomic classes. A slew of 
epidemiological studies have documented the clonal, 
worldwide spread of infectious disease entities such 
as MDR S. pneumoniae from specific regions of the 
world. Also, the use of antibiotics in animal husbandry 
has been shown to foster human colonization with drug-
resistant microbes (Levy et al., 1976). There are com-
pelling data that link use of agents like virginiamycin (a 
streptogramin) and avoparcin (a glycopeptide) in animal 
husbandry to clinical drug-resistant strains.
Bacteria adopt intricate strategies to avoid the lethal 
effects of antibiotics. Awareness of these mechanisms 
of resistance can help in the design of new drugs. As 
we face this critical problem, we need to be aware of 
the fluidity of the microbial genome and the relative ease 
with which resistance can emerge by mutation or gene 
acquisition. Recognizing the potential for the emer-
gence of resistance should garner newfound respect for 
the discovery of new agents so urgently needed to cure 
infectious diseases.
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